

News Releases

All Years



Search

GO

[Advanced Search](#)

Jul 17, 2019

Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2019, and...

Jul 8, 2019

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors

- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new invitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and...

Jun 19, 2019

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

- Interim Phase 2a Data Highlight Efficacy and Safety Results of Cerdulatinib Alone and in Combination with Rituximab -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

May 28, 2019

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

May 28, 2019 PDF Version SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and...

May 22, 2019

Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage

- Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage -

SOUTH SAN FRANCISCO, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new analysis of data from an important subgroup...

Show 5



per

[<](#) [1](#) ... [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) ... [54](#) [>](#)

page



<https://investors.portola.com/news-releases?ID=2376001&c=198136&p=irol-newsArticle&o=35>